Vanda Pharmaceuticals Inc. (VNDA) News

Vanda Pharmaceuticals Inc. (VNDA): $18.30

0.26 (+1.44%)

POWR Rating

Component Grades













Add VNDA to Watchlist
Sign Up

Industry: Biotech


of 509

in industry

Filter VNDA News Items

VNDA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VNDA News Highlights

  • VNDA's 30 day story count now stands at 2.
  • Over the past 1 day, the trend for VNDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest VNDA News From Around the Web

Below are the latest news stories about Vanda Pharmaceuticals Inc that investors may wish to consider to help them evaluate VNDA as an investment opportunity.

Investors in Vanda Pharmaceuticals (NASDAQ:VNDA) have made a decent return of 66% over the past year

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

Yahoo | October 15, 2021

Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board, will take part in a virtual fireside chat at 1:30 PM ET.

Yahoo | October 14, 2021

Vanda (VNDA) Upgraded to Buy: Here's Why

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | September 21, 2021

Notable Vanda Pharmaceuticals Insider Trades $418.64 Thousand In Company Stock

Aranthan S. Jones Ii, Chief Corporate Affairs Officer at Vanda Pharmaceuticals (NASDAQ:VNDA), made a large buy and sell of company shares on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Aranthan S. Jones Ii purchased 12,119 Vanda Pharmaceuticals shares at prices ranging from $11.32 to $12.27 per share for a total of $141,250 on September 15. They then sold their shares on the same day in the open market.

Yahoo | September 17, 2021

Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021. Vanda management will host investor meetings. Vanda has updated its corporate presentation, which may be accessed on Vanda's website,, by clicking on the Investors tab and following the Corporate Presentation link.

Yahoo | September 8, 2021

Should Weakness in Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at Vanda Pharmaceuticals' (NASDAQ:VNDA) recent performance, when its stock has...

Yahoo | August 18, 2021

Novavax Names Jim Kelly CFO; Appoints Nasir Egal As SVP, Quality Assurance

(RTTNews) - Novavax, Inc. (NVAX) announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer and Treasurer. Kelly joins Novavax from Supernus Pharmaceuticals, where he served as CFO. Previously, he was CFO and Treasurer at Vanda Pharmaceuticals. The company also appointed Nasir Egal as Senior Vice President,

Business Insider Markets | August 16, 2021

Oil Up Over Brighter Fuel Demand Outlook, but COVID-19 Challenges Remain

By Gina Lee

Yahoo | August 10, 2021

Vanda (VNDA) Loses 21.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | August 5, 2021

Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.

Yahoo | August 3, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6347 seconds.